Sus Clinicals accelerates qualification of potentially life-saving cancer therapeutics through our proprietary pig-based preclinical testing services. In collaboration with top research institutions with large animal testing capability, our predictive model can better identify those drugs, diagnostics, and devices that have the highest potential for success in human clinical trials.
Sus Clinicals, Inc. is delighted to participate in this year’s American Association of Cancer Research Annual Meeting in Chicago, beginning on Friday, April 25. Sus Clinicals’ Principal R&D Scientist Dr. Mahmoud Khalafalla will be
Sus Clinicals will present two sessions on the Oncopig Cancer Model® on Monday, March 25, at SIR2024 in Salt Lake City, UT.
The Swine in Biomedical Research conference will be held June 14-18, 2024, in Madison, WI. Hosted again by the University of Wisconsin, SBR2024 will convene researchers from around the world
Experts from Sus Clinicals will attend the 8th Swine in Biomedical Research Conference taking place June 14-18, 2024 at the University of Wisconsin in Madison.
Sus Clinicals will present two sessions on the Oncopig Cancer Model® on Monday, March 25, at SIR2024 in Salt Lake City.
Sus Clinicals, Inc. announced today that Dr. Lawrence Schook has been elected to the Company’s Board of Directors
Sus Clinicals (“Sus” rhymes with “moose”) is named for the genus of wild and domestic pigs (Sus scrofa). We make use of the remarkable similarity between pigs and humans to help our healthcare client partners develop breakthrough therapeutics more efficiently and more quickly, helping to save lives. Our proprietary large animal genome editing research platform is FDA-cleared and accelerates preclinical research. We aim to bridge the gap between fast but minimally predictive mouse-based testing and costly, time-consuming, and high-risk human clinical trials.
Our genetically-engineered Oncopig® enables testing of medical devices, diagnostics, and drugs to assess their efficacy and safety in humans by inducing relevant tumors and comorbidities on demand. Although our initial focus is on cancer, our porcine platform is well-suited to support work against a full spectrum of diseases in the future.
